Miralax Powder, For Solution
NDC Package 11523-4357-2
Package Information
Miralax (polyethylene glycol 3350) powders is a medication used to treat occasional constipation. This formulation utilizes a powder, for solution delivery system. Marketed by Bayer Healthcare Llc., this product is identified by NDC 11523-4357 and is authorized under FDA application NDA022015.
Identification & Billing
- RxCUI: 876193 - polyethylene glycol 3350 17 GM Powder for Oral Solution
- RxCUI: 876193 - polyethylene glycol 3350 17000 MG Powder for Oral Solution
- RxCUI: 876195 - MiraLAX 17 GM Powder for Oral Solution
- RxCUI: 876195 - polyethylene glycol 3350 17000 MG Powder for Oral Solution [Miralax]
- RxCUI: 876195 - Miralax 17 GM Powder for Oral Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 11523 - Bayer Healthcare Llc.
- 11523-4357 - Miralax
- 11523-4357-2 - 2 CARTON in 1 CARTON / 20 PACKET in 1 CARTON / 17 g in 1 PACKET
- 11523-4357 - Miralax
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (11523-4357). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 11523-4357-2 identifies a specific commercial package of 2 carton in 1 carton / 20 packet in 1 carton / 17 g in 1 packet of Miralax, a human over the counter drug labeled by Bayer Healthcare Llc.. This powder, for solution is formulated for oral use and contains polyethylene glycol 3350 as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bayer Healthcare Llc. on February 01, 2007. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is used to treat occasional constipation. It works by holding water in the stool to soften the stool and increases the number of bowel movements. It is known as an osmotic-type laxative. This medication is also available without a prescription. If you are taking this medication for self-treatment, it is important to read the manufacturer's package instructions carefully so you know when to consult your doctor or pharmacist. (See also Precautions.)
How is this Bayer Healthcare Llc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 11523435702. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.